By Alexis Blue, University Communications | September 20, 2012
Researchers think the drug 3K3A-APC, currently undergoing clinical trials in Europe, may help reduce brain damage and improve motor skills after a stroke.Continue reading
Category Archives: AZBio News
Medtronic seeks pharma partners for Alzheimer’s treatments
According to a receint article in FierceMedicalDevices, Medtronic ($MDT) believes its pump technology could pair well with the next generation of Alzheimer’s treatments, and the company is on the hunt for pharmaceutical partners.Continue reading
Mayo Clinic spies enzyme that destroys brain-clogging Alzheimer’s protein
Mayo Clinic scientists believe they’ve found an enzyme that could defeat Alzheimer’s disease by destroying the brain-clogging protein that is a hallmark of the condition as it advances.Continue reading
AZBio Announces Finalists for 2012 Bioscience Company of the Year
The 2012 Bioscience Company of the Year will be announced at the AZBio Awards on October 23, 2012 at the Phoenix Convention Center.Continue reading
UACC Study looks at Broccoli and Tamoxifen – Participants Needed
A compound found in broccoli might be able to enhance the health-promoting effects of the breast cancer drug, Tamoxifen.Continue reading
HealthTell Opens in Innovations Incubator
Chandler, AZ—HealthTell Inc., a new biotechnology start-up company, is expanding its operations to the Innovations Incubator in Chandler. HealthTell has developed a system for providing “immunosignatures” for early screening and diagnosis of multiple diseases such as cancer and Alzheimer’s.Continue reading
UA College of Medicine Researcher Gets $1.9 Million Federal Grant
Faculty Member Earns Prestigious Award for Schizophrenia ResearchContinue reading
NEA’s David Mott on what VC firm’s $2.6B fund means for biotech (biotechVC)
New Enterprise Associates packs financial firepower like few other venture capital outfits today, particularly those investing in biotech. Fresh off closing a diversified venture fund of $2.6 billion revealed in July, NEA is expected to spend roughly a third of its capital from the fund on healthcare investments primarily in the biopharma industry, General Partner David Mott (who sold MedImmune to AstraZeneca ($AZN) for $15.6 billion in 2007), told FierceBiotech.Continue reading
Brain State Technologies® Opens New Worldwide Brainwave Optimization™ Centers
With a global reach of 19 countries, partner network expands across U.S., Canada, Panama and Australia.Continue reading
Rick Myers To Receive the 2012 AZBio Public Service Award
A widely respected and tireless civic leader, Rick Myers is a visionary and a strong advocate for promoting the biosciences in Arizona. Rick serves as the Governor-appointed Chair for the Arizona Board of Regents and advocates for growing the research enterprise and promoting biosciences.Continue reading